OQROGet OQRO Pro
Insider trade

Merck (MRK)Officer sold ~$4.47M

David Michael Williams, Officer at Merck, sold ~$4.47M of Merck shares.

~$4.47M
Approx. value · 35K sh @ $128.77
32K
Holds after · shares reported
Traded
Aug 5, 2026
Filed
Aug 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 27, 2026CongressDisclosed sale of MRK — reported range $15,001 - $50,000
  2. Jun 12, 2026FDAFDA drug approval: Welireg
  3. Jun 12, 2026FDAFDA drug approval: Keytruda
  4. Jun 12, 2026FDAFDA drug approval: Keytruda Qlex
  5. Jun 12, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  6. Jun 12, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  7. Jun 23, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  8. Jun 24, 2026FDAFDA drug approval: Keytruda
  9. Jun 24, 2026FDAFDA drug approval: Keytruda Qlex
  10. Jul 10, 2026FDAFDA drug approval: Keytruda
  11. Jul 10, 2026FDAFDA drug approval: Keytruda Qlex
  12. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
  13. Aug 5, 2026 · this disclosureInsider · Their largest sale since 2023Officer sold ~$4.47M of MRK shares in the open market

What came next

  1. Aug 5, 2026Insider · 2 peopleInsiders: 5 sales (~$4.7M)
  2. Aug 6, 2026Insider · 2 peopleInsiders: 4 sales (~$2.8M)
  3. Aug 10, 2026InsiderOfficer sold ~$2.71M of MRK shares in the open market
  4. Aug 11, 2026Insider · 1 personInsiders: 2 sales (~$1.7M)
  5. Aug 12, 2026Insider · 2 peopleInsiders: 3 sales (~$12.3M)
  6. Aug 13, 2026InsiderOfficer sold ~$1.35M of MRK shares in the open market
  7. Aug 19, 2026Congress · 1 personMembers of Congress: 2 purchases
  8. Sep 14, 2026Federal contract · $1.6M obligatedDepartment of Health and Human Services awarded Merck: $1.63M obligated to date
  9. Sep 21, 2026FDAFDA drug approval: Winrevair
  10. Sep 24, 2026FDAFDA drug approval: Welireg
  11. Sep 24, 2026CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Merck

For Merck, OQRO holds 26 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 123 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by David Michael Williams, EVP,Chief Info&Digital Officer

The full history of David Michael Williams, EVP,Chief Info&Digital Officer is on the profile page.

How this filing works

Other disclosures at Merck

Everything OQRO holds on this company is on its MRK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data